[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521269":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":10,"centralContacts":32,"locations":38,"responsibleParty":54,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"New Valley University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"1",null,"Diabetics",[13,14,15],"Diagnostic Test: Glycated hemoglobin (HbA1C)","Diagnostic Test: RDW","Diagnostic Test: Lipid profile",{"label":17,"type":10,"description":18,"interventionNames":19},"2","Healthy control",[13,14,15],[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","Glycated hemoglobin (HbA1C)","Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )",[9,17],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":10},"RDW",[9,17],{"type":22,"name":30,"description":24,"armGroupLabels":31,"otherNames":10},"Lipid profile",[9,17],[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Asmaa N Hussein, MD","CONTACT","01065161752","asmaanady_1010@med.nvu.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":10,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"New Valley University- Faculty of Medicine","RECRUITING","Al Khārjah","Egypt","EG",{"type":46,"coordinates":47},"Point",[48,49],30.54653,25.45101,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":36,"phoneExt":10,"email":37},"Asmaa Hussein, MD",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Asmaa Nady Hussein","Lecturer of Internal Medicine and Clinical Hematology","100521269","relationship-between-red-cell-distribution-width-rdw-and-hba1c-in-patients-with-type-2-diabetes-mellitus-after-glycemic-control-100521269",false,"NCT06067399","Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control","Inclusion Criteria:\n\n* Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)\n\nExclusion Criteria:\n\n1. Patients diagnosed to have type 1 diabetes.\n2. Patients are diagnosed to have secondary diabetes.\n3. Clinical states associated with increased RDW:\n\n   * Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.\n   * After blood transfusions\n   * Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.",true,"ALL","40 Years",{"count":68,"type":69},250,"ESTIMATED","OBSERVATIONAL","Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.",[73],"Type 2 Diabetes","2025-08-12",{"date":76,"type":77},"2025-08-15","ACTUAL",{"date":79,"type":69},"2025-12-01",{"date":81,"type":69},"2026-06-30",{"name":5,"class":6},1]